Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects

• Status: Completed
• Trial end date: 2011-11-22
• Target enrollment: 0
• Participant gender: All

Summary

This trial was conducted in Asia. The aim of this trial was to investigate the pharmacokinetic properties (the effect of the investigated drug on the body) of NN1250 (insulin degludec) in healthy Chinese subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin

Criteria

Inclusion Criteria:

• Male or female Chinese subject aged 18-45 years (both inclusive)

• Considered generally healthy upon completion of medical history, physical examination, vital signs and electrocardiogram (ECG), as judged by the Investigator

• Body mass index 19.0-24.0 kg/m^2 (both inclusive)

Exclusion Criteria:

• A history of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial product to the subject

• Subject who has donated any blood or plasma in the past month or more than 400 mL within 3 months prior to screening

• Not able or willing to refrain from smoking during the inpatient period